Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 13880
Country/Region: Uganda
Year: 2016
Main Partner: Makerere University
Main Partner Program: School of Public Health
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $3,697,229 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $529,739
Care: TB/HIV (HVTB) $128,366
Care: Pediatric Care and Support (PDCS) $209,218
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $200,000
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $540,952
Testing: HIV Testing and Counseling (HVCT) $335,971
Sexual Prevention: Other Sexual Prevention (HVOP) $399,844
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $217,371
Treatment: Adult Treatment (HTXS) $1,073,772
Treatment: Pediatric Treatment (PDTX) $61,996
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age/Sex: <10 Female 2017 93
GEND_GBV Age/Sex: <10 Male 2017 56
GEND_GBV Age/Sex: 10-14 Female 2017 257
GEND_GBV Age/Sex: 10-14 Male 2017 56
GEND_GBV Age/Sex: 15-19 Female 2017 455
GEND_GBV Age/Sex: 15-19 male 2017 88
GEND_GBV Age/Sex: 20-24 Female 2017 457
GEND_GBV Age/Sex: 20-24 Male 2017 93
GEND_GBV Age/Sex: 25-49 Female 2017 186
GEND_GBV Age/Sex: 25-49 Male 2017 93
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 166
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 402
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 1,432
GEND_GBV Number of people receiving post-GBV care 2017 1,834
GEND_GBV Sum of Age/Sex Disaggregates 2017 462
HRH_PRE By Graduates: Other 2017 115
HRH_PRE Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre 2017 115
HRH_PRE Sum of Graduates disaggregates 2017 115
HTS_TST Age/sex: <1 2017 1,050
HTS_TST Age/sex: 1-9 2017 3,455
HTS_TST Age/sex: 10-14 Female 2017 2,984
HTS_TST Age/sex: 10-14 Male 2017 2,974
HTS_TST Age/sex: 15-19 Female 2017 11,979
HTS_TST Age/sex: 15-19 Male 2017 21,931
HTS_TST Age/sex: 20-24 Female 2017 17,971
HTS_TST Age/sex: 20-24 Male 2017 32,895
HTS_TST Age/sex: 25-49 Female 2017 27,555
HTS_TST Age/sex: 25-49 Male 2017 50,441
HTS_TST Age/sex: 50+ Female 2017 2,393
HTS_TST Age/sex: 50+ Male 2017 4,384
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 5,238
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 5,225
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 59,898
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 109,651
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 180,012
HTS_TST Service Delivery Point (Facility): Index testing 2017 10,215
HTS_TST Service Delivery Point (Facility): Inpatient 2017 26,135
HTS_TST Service Delivery Point (Facility): Other PITC 2017 10,954
HTS_TST Service Delivery Point (Facility): Outpatient 2017 36,257
HTS_TST Service Delivery Point (Facility): Pediatric 2017 8,440
HTS_TST Service Delivery Point (Facility): PMTCT 2017 23,496
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 980
HTS_TST Service Delivery Point (Facility): VMMC 2017 63,535
HTS_TST Sum of Age/Sex disaggregates 2017 175,507
HTS_TST Sum of Aggregated Age/Sex <15 2017 10,463
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 169,549
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 180,012
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 119
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 123
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 592
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 400
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 894
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 604
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 1,366
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 921
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 113
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 75
HTS_TST_POS Test Result by Age: Positive: <1 2017 48
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 147
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 218
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 219
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 2,965
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 2,000
KP_PREV By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 658
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2017 658
KP_PREV Total estimated number of key population in the catchment area 2017 1,162
KP_PREV_den By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) 2017 1,162
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 6,268
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14 2017 1,888
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17 2017 1,246
OVC_SERV Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24 2017 3,134
PMTCT_ART Already on ART at beginning of current pregnancy 2017 1,428
PMTCT_ART New on ART 2017 1,026
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 23,739
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 1,619
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 452
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 18
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 81
PMTCT_EID Sum of Infant Age disaggregates 2017 2,071
PMTCT_STAT By: Known positives at entry 2017 1,721
PMTCT_STAT By: Number of new positives identified 2017 872
PMTCT_STAT Number of new ANC and L&D clients 2017 24,346
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 23,739
PMTCT_STAT Sum of Positives Status disaggregates 2017 2,593
PP_PREV Aggregated Age/sex: <15 Female 2017 803
PP_PREV Aggregated Age/sex: <15 Male 2017 741
PP_PREV Aggregated Age/sex: 15+ Female 2017 21,722
PP_PREV Aggregated Age/sex: 15+ Male 2017 947
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 24,212
PP_PREV Total number of people in the target population 2017 38,246
PrEP_NEW Female 15-19 2017 504
PrEP_NEW Female 20-24 2017 231
PrEP_NEW Female 25-49 2017 136
PrEP_NEW Female 50+ 2017 13
PrEP_NEW Male 15-19 2017 372
PrEP_NEW Male 20-24 2017 99
PrEP_NEW Male 25-49 2017 136
PrEP_NEW Male 50+ 2017 12
PrEP_NEW Number of individuals who have received antiretroviral preexposure 2017 1,503
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 56
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 119
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 177
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 177
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 1,932
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 192
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 579
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 1,161
TB_SCREENDX Screen Result: Screened Positive for TB 2017 481
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 14,854
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 7,647
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 880
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 776
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 24,157
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 11
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 172
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 14
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 320
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 517
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 517
TX_CURR Age/Sex: <1 2017 60
TX_CURR Age/Sex: <1-9 2017 406
TX_CURR Age/Sex: 10-14 Female 2017 639
TX_CURR Age/Sex: 10-14 Male 2017 551
TX_CURR Age/Sex: 15-19 Female 2017 740
TX_CURR Age/Sex: 15-19 Male 2017 229
TX_CURR Age/Sex: 20-24 Female 2017 3,415
TX_CURR Age/Sex: 20-24 Male 2017 1,528
TX_CURR Age/Sex: 25-49 Female 2017 9,959
TX_CURR Age/Sex: 25-49 Male 2017 5,506
TX_CURR Age/Sex: 50+ Female 2017 740
TX_CURR Age/Sex: 50+ Male 2017 384
TX_CURR Aggregated Age/Sex: <15 Female 2017 880
TX_CURR Aggregated Age/Sex: <15 Male 2017 776
TX_CURR Aggregated Age/Sex: 15+ Female 2017 14,854
TX_CURR Aggregated Age/Sex: 15+ Male 2017 7,647
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 24,157
TX_CURR Sum of age/sex disaggregates 2017 969
TX_CURR Sum of Aggregated Age/Sex <15 2017 1,656
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 22,501
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 24,157
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 180
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 158
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 4,028
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 2,079
TX_NEW By Age/Sex: <1 2017 9
TX_NEW By Age/Sex: 1-9 2017 82
TX_NEW By Age/Sex: 10-14 Female 2017 136
TX_NEW By Age/Sex: 10-14 Male 2017 111
TX_NEW By Age/Sex: 15-19 Female 2017 199
TX_NEW By Age/Sex: 15-19 Male 2017 65
TX_NEW By Age/Sex: 20-24 Female 2017 925
TX_NEW By Age/Sex: 20-24 Male 2017 414
TX_NEW By Age/Sex: 25-49 Female 2017 2,699
TX_NEW By Age/Sex: 25-49 Male 2017 1,496
TX_NEW By Age/Sex: 50+ Female 2017 205
TX_NEW By Age/Sex: 50+ Male 2017 104
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 6,445
TX_NEW Sum of Age/Sex disaggregates 2017 6,354
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 6,445
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 19,326
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 17,396
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 632
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 557
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 10,691
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 5,516
TX_PVLS Numerator: Indication: Routine 2017 17,396
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 703
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 623
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 11,879
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 6,121
TX_PVLS_den Denominator: Indication: Routine 2017 19,326
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 31
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 61
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 58
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 52
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 69
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 242
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 8
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 707
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,614
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 51
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 549
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 69
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 81
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,052
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,240
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 3,442
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 3,865
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 35
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 64
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 61
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 63
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 75
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 273
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 507
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 800
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,809
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 55
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 122
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 74
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 87
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,191
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,513
VMMC_CIRC By Age: 10-14 2017 24,782
VMMC_CIRC By Age: 15-19 2017 18,427
VMMC_CIRC By Age: 20-24 2017 8,902
VMMC_CIRC By Age: 25-29 2017 5,079
VMMC_CIRC By Age: 30-49 2017 5,079
VMMC_CIRC By Age: 50+ 2017 1,266
VMMC_CIRC By circumcision technique: Device-based VMMC 2017 6,361
VMMC_CIRC By circumcision technique: Surgical VMMC 2017 57,174
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2017 63,535
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2017 63,535
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2017 53,377